Formulations

Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More


  • No Image
    Noel Pharma Pvt Ltd

    Noel Pharma India Pvt Ltd was initially started as a proprietorship concern in 1998 as ?Anros Pharma? at Hyderabad, Telangana. In 2005, Anros Pharma acquired all the intangible

  • No Image
    Novartis India Ltd

    Novartis (NYSE: NVS) is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceutica

  • No Image
    Nutraplus Product India Ltd

    Nutraplus India has started commercial production of anti-malarial drug Lumefantrine at its new plant at Tarapur in Maharashtra. Earlier, the company has been manufacturing int